Jadwal Sholat

Memuat jadwal sholatโ€ฆ

Kedokteran & Kesehatan editorial

Open AccessOA2022

Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial

In the HPTN 084 trial, injectable cabotegravir reduced HIV incidence by 88% compared with daily oral TDF-FTC among 3,224 women in sub-Saharan Africa, despite similar safety profiles.
S. Delany-Moretlwe; J. Hughes; P. Bock; S. Ouma; Portia Hunidzarira; D. Kalonji; N. Kayange; J. Makhema; P. Mandima; Carrie-Anne Mathew; E. Spooner; J. Mpendo; P. Mukwekwerere; N. Mgodi; P. N. Ntege; G. Nair; C. Nakabiito; H. Nuwagaba-Biribonwoha; R. Panchia; Nishanta Singh; B. Siziba; J. Farrior; S. Rose; P. Anderson; S. Eshleman; M. Marzinke; C. Hendrix; Stephanie Beigel-Orme; S. Hosek; E. Tolley; N. Sista; A. Adeyeye; J. Rooney; A. Rinehart; W. Spreen; K. Smith; B. Hanscom; M. Cohen; M. Hosseinipour; A. Asmelash; Alice Sehurutshi; Allan Baguma; A. Marais; B. Kawoozo; B. P. Malinga; B. G. Mirembe; B. Okech; B. Esterhuizen; Caroline Murombedzi; Daphne Gadama; Eldinah Hwengwere; E. Roos; E. S. Magada; Emily Shava; E. Piwowar-Manning; Eunice Tahuringana; Felix Muhlanga; F. Conradie; Frank Angira; Gertrude Nanyonjo; Girisha Kistnasami; Hazzie Mvula; Ishana Naidoo; Jacob Horak; Jane Jere; Jeeva Moodley; Katherine Shin; K. Nel; Kevin Bokoch; L. Birungi; L. Emel; Maletsatsi Monametsi; Marvelous Sibanda; M. Mutambanengwe; Miria Chitukuta; Moleen Matimbira; Muchaneta Bhondai-Mhuri; Ntokozo Sibisi; N. Morar; Netsai Mudzonga; P. Natureeba; P. Richardson; P. Musara; Pippa R Macdonald; R. Nkambule; Repelang Mosime; Rhonda R. White; R. Berhanu; Ritha Ncube-Sihlongonyane; Rogers Sekabira; Samantha S. Siva; Saresha Pillay; S. Govender; Sheiala Bamweyana; Siyabonga Nzimande; S. Innes; S. Dadabhai; T. Samandari; Tchangani Tembo; Thandie Lungu Mabedi; Thandiwe Chirenda; Tinashe Chidemo; Victor Mudhune; Vikesh Naidoo; W. Samaneka; Yaw Agyei; Y. Musodza; Y. Fourie; Z. Gaffoorยท The Lancetยท 2022ยท DOI 10.1016/S0140-6736(22)00538-4

The core problem

Oral pre-exposure prophylaxis (PrEP) has been introduced in more than 70 countries, including many in sub-Saharan Africa, but women face considerable barriers to daily pill-taking, such as stigma, judgement, and fear of violence. Safe and effective long-acting agents for HIV prevention are urgently needed for women. The HPTN 084 trial aimed to evaluate the safety and efficacy of injectable cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine (TDF-FTC) for HIV prevention in HIV-uninfected women.

Innovation

HPTN 084 was a phase 3, randomised, double-blind, double-dummy, active-controlled, superiority trial conducted at 20 clinical research sites in seven countries in sub-Saharan Africa (ClinicalTrials.gov NCT03164564). Eligible participants were assigned female sex at birth, aged 18โ€“45 years, reported at least two episodes of vaginal intercourse in the previous 30 days, were at risk of HIV infection based on an HIV risk score, and agreed to use a long-acting reversible contraceptive method. Participants were randomly assigned (1:1) to either active cabotegravir with TDF-FTC placebo (cabotegravir group) or active TDF-FTC with cabotegravir placebo (TDF-FTC group). Study staff and participants were masked to study group allocation, with the exception of the site pharmacist responsible for study product preparation. Participants were prescribed 5 weeks of daily oral product followed by intramuscular injections every 8 weeks after an initial 4-week interval load, alongside daily oral pills. Participants who discontinued injections were offered open-label daily TDF-FTC for 48 weeks. The primary endpoints were incident HIV infection in the intention-to-treat population and clinical and laboratory events of grade 2 or higher in all women who received at least one dose of study product.
Introduction
Oral pre-exposure prophylaxis (PrEP) has been introduced in more than 70 countries, including many in sub-Saharan Africa, but women face considerable barriers to daily pill-taking, such as stigma, judgement, and fear of violence. Safe and effective long-acting agents for HIV prevention are urgently needed for women. The HPTN 084 trial aimed to evaluate the safety and efficacy of injectable cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine (TDF-FTC) for HIV prevention in HIV-uninfected women.

Why it matters

Although both products for HIV prevention were generally safe, well tolerated, and effective, cabotegravir was superior to TDF-FTC in preventing HIV infection in women. The hazard ratio of 0.12 indicates an 88% reduction in HIV incidence with cabotegravir compared with daily oral TDF-FTC. The low adherence to daily oral TDF-FTC (only 42.1% of plasma samples showed tenofovir concentrations consistent with daily use) likely contributed to the difference in efficacy, highlighting the challenge of daily pill-taking for women in this setting. Injection coverage was high (93%), suggesting that long-acting injectable cabotegravir is a feasible and acceptable prevention option. Injection site reactions were more common with cabotegravir but did not lead to discontinuation. No congenital birth anomalies were reported, and pregnancy incidence was low. These findings support the use of injectable cabotegravir as a promising HIV prevention strategy for women in sub-Saharan Africa.

Who should read this

Pembaca Research Digest dan praktisi rumpun ini.

Opening member contentโ€ฆ